Evidence map›Paper›PMID 39934879›Full record

ArticleTrials2025

Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trial.

Robert K Mahar, Anna McGlothlin, Michael Dymock, Lauren Barina, Marc Bonten, Asha Bowen, Matthew P Cheng, Nick Daneman, Anna L Goodman, Todd C Lee and 16 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05137119 phase4recruitingnot on this map

Staphylococcus Aureus Network Adaptive Platform Trial

TypeinterventionalSponsorUniversity of MelbourneRan2022 to 2028Enrolled8,000ConditionsStaphylococcus Aureus BacteremiaArmsCefazolin, Penicillin, Clindamycin, Vancomycin, Effectiveness of early switch to oral antibiotics
NCT07384702 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Phase 2 Platform Randomized, Multicentre and Open Trial on the Efficacy and Safety of Clopidogrel as Adjuvant Drug in Staphylococcus Aureus Bacteraemia (CLOPI-SNAP)

TypeinterventionalSponsorFundación Pública Andaluza para la gestión de la Investigación en SevillaRan2026 to 2030Enrolled230ConditionsBacteremia Due to Staphylococcus AureusArmsClopidogrel, No antiplatelet treatment
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Robert K MaharCentre for Epidemiology, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia. robert.mahar@unimelb.edu.au.
Anna McGlothlinBerry Consultants, LLC, Austin, TX, USA.
Michael DymockWesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia.
Lauren BarinaDepartment of Infectious Diseases, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Marc BontenJulius Centre for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Asha BowenWesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia.
Matthew P ChengDivision of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montreal, Canada.
Nick DanemanDivision of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
Anna L GoodmanMRC Clinical Trials Unit at University College London, London, UK.
Todd C LeeDivision of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montreal, Canada.
Roger J LewisBerry Consultants, LLC, Austin, TX, USA.
Thomas LumleyDepartment of Statistics, University of Auckland, Auckland, New Zealand.
Alistair R D McLeanMethods and Implementation Support for Clinical Research Hub, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia.
Zoe McQuiltenSchool of Public Health and Preventative Medicine, Monash University, Melbourne, Australia.
Jocelyn MoraDepartment of Infectious Diseases, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
David L PatersonADVANCE-ID, Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
David J PriceCentre for Epidemiology, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Australia.
Jason RobertsFaculty of Medicine, University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Australia.
Tom SnellingWesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia.
Jonas TverringDepartment of Infectious Diseases, Helsingborg Hospital, Helsingborg, Sweden.
Steve A WebbAustralian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia.
Dafna YahavInfectious Diseases Unit, Sheba Medical Center, Ramat-Gan, Israel.
Joshua S DavisInfection Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Sydney, Australia.
Steven Y C TongDepartment of Infectious Diseases, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Julie A MarshWesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, WA, Australia.
SNAP Global Trial Steering Committee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platform trials have become widely adopted across multiple disease areas over recent years, however, guidelines for operationalising these trials have not kept pace. We outline a series of documents that summarise the statistical components, and implicit processes, of the Staphylococcus aureus Network Adaptive Platform (SNAP) trial to provide an informal template for other researchers and reviewers of platform trials. We briefly summarise the content and role of the core protocol, statistical appendix, domain-specific appendices, simulation report, statistical implementation guides, data safety and monitoring committee (DSMC) reports, and domain-specific statistical analysis plans and final reports, and a transparent governance structure that ensures separate blinded and unblinded statistical teams. In the absence of guidelines or checklists for platform trial statistical documents, we hope to provide useful guidance to others in terms of what has worked so far for the SNAP trial, stimulate discussion, and inform a future consensus.Trial registration NCT05137119 . Registered on 30 November 2021.

Indexed as

DocumentationRandomized Controlled Trials as TopicResearch DesignStaphylococcal InfectionsStaphylococcus aureusData Interpretation, StatisticalHumansMulticenter Studies as Topic

Identifiers

PMID39934879
PMCPMC11817021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.